ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Vanda Pharmaceuticals and Eli Lilly side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Vanda PharmaceuticalsEli Lilly
studies on the registry822,262
open to participants now16174
phase 3 studies under way12104
reach primary completion within a year6104
programswith a study of their own in two years993+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseVanda PharmaceuticalsEli Lilly
Phase 100%

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%
Phase 2

Vanda Pharmaceuticals: 3 of its 9 programs at phase 2

  1. VSJ-110phase 2
  2. trichostatin Aphase 2
  3. VCA-894Aphase 2
33%

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%
Phase 3

Vanda Pharmaceuticals: 4 of its 9 programs at phase 3

  1. tradipitantphase 3
  2. ponesimodphase 3
  3. milsaperidonephase 3
  4. VQW-765phase 3
44%

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%
Approved, new studies

Vanda Pharmaceuticals: 2 of its 9 programs at approved, new studies

  1. tasimelteonapproved, new study
  2. iloperidoneapproved, new study
22%

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Vanda Pharmaceuticals3 readouts · 2 phase 3·

Vanda Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. VQW-765phase 3 · Dec 0 · NCT07221578
  2. tradipitantphase 3 · Dec 1 · NCT07446439
··

Vanda Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. VCA-894Aphase 2 · Mar 0 · NCT07223632
·······
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Vanda Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Eli Lilly

New programs 9

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionVanda PharmaceuticalsEli Lilly
Renal Insufficiencyboth · compare here

Vanda Pharmaceuticals in Renal Insufficiency: 1 program

  1. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Renal Insufficiency in search

Eli Lilly in Renal Insufficiency: 6 programs

  1. olomorasibphase 3
  2. tersolisibphase 3
  3. lepodisiranphase 3
  4. muvalaplinphase 3
  5. pirtobrutinibapproved, new study

and 1 more — sign in to see them all

Their studies: Eli Lilly’s studies of Renal Insufficiency in search

Psoriasisboth · compare here

Vanda Pharmaceuticals in Psoriasis: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Psoriasis in search

Eli Lilly in Psoriasis: 5 programs

  1. eltrekibartphase 2
  2. simepdekinraphase 2
  3. DC-806phase 2
  4. Tirzepatideapproved, new study
  5. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Psoriasis in search

Colitis, Ulcerativeboth · compare here

Vanda Pharmaceuticals in Colitis, Ulcerative: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Colitis, Ulcerative in search

Eli Lilly in Colitis, Ulcerative: 4 programs

  1. zotemtegrastphase 2
  2. LY4395089phase 2
  3. eltrekibartphase 2
  4. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Colitis, Ulcerative in search

Parkinson Diseaseboth · compare here

Vanda Pharmaceuticals in Parkinson Disease: 1 program

  1. iloperidoneapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Parkinson Disease in search

Eli Lilly in Parkinson Disease: 3 programs

  1. parunoflastphase 2
  2. LY3884961phase 2
  3. LY4006896phase 1

Their studies: Eli Lilly’s studies of Parkinson Disease in search

Depressive Disorder, Majorboth · compare here

Vanda Pharmaceuticals in Depressive Disorder, Major: 2 programs

  1. milsaperidonephase 3
  2. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Depressive Disorder, Major in search

Eli Lilly in Depressive Disorder, Major: 1 program

  1. brenipatidephase 3

Their studies: Eli Lilly’s studies of Depressive Disorder, Major in search

Dermatitis, Atopicboth · compare here

Vanda Pharmaceuticals in Dermatitis, Atopic: 1 program

  1. tradipitantphase 3

Their studies: Vanda Pharmaceuticals’ studies of Dermatitis, Atopic in search

Eli Lilly in Dermatitis, Atopic: 2 programs

  1. baricitinibapproved, new study
  2. lebrikizumabapproved, new study

Their studies: Eli Lilly’s studies of Dermatitis, Atopic in search

Hypertensionboth · compare here

Vanda Pharmaceuticals in Hypertension: 1 program

  1. iloperidoneapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Hypertension in search

Eli Lilly in Hypertension: 1 program

  1. orforglipronphase 3

Their studies: Eli Lilly’s studies of Hypertension in search

Liver Diseasesboth · compare here

Vanda Pharmaceuticals in Liver Diseases: 1 program

  1. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Liver Diseases in search

Eli Lilly in Liver Diseases: 1 program

  1. lepodisiranphase 3

Their studies: Eli Lilly’s studies of Liver Diseases in search

Multiple Sclerosisboth · compare here

Vanda Pharmaceuticals in Multiple Sclerosis: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Multiple Sclerosis in search

Eli Lilly in Multiple Sclerosis: 1 program

  1. sevoloprubartphase 2

Their studies: Eli Lilly’s studies of Multiple Sclerosis in search

Nauseaboth · compare here

Vanda Pharmaceuticals in Nausea: 1 program

  1. tradipitantphase 3

Their studies: Vanda Pharmaceuticals’ studies of Nausea in search

Eli Lilly in Nausea: 1 program

  1. GIPR Agonist LY3537021phase 2

Their studies: Eli Lilly’s studies of Nausea in search

Phobia, Socialboth · compare here

Vanda Pharmaceuticals in Phobia, Social: 1 program

  1. VQW-765phase 3

Their studies: Vanda Pharmaceuticals’ studies of Phobia, Social in search

Eli Lilly in Phobia, Social: 1 program

  1. EMP-01phase 2

Their studies: Eli Lilly’s studies of Phobia, Social in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Vanda Pharmaceuticals 4 of 9 · Eli Lilly 50 of 93 programs (26 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).